{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:55:11Z","timestamp":1792068911700,"version":"4.4.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015777","name":"Division of Research Capacity Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015777","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016979","name":"National Treasury","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000883","name":"University of Bristol","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000883","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["SRUG2205035984"],"award-info":[{"award-number":["SRUG2205035984"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bmc.2026.118810","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:05:50Z","timestamp":1790348750000},"page":"118810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Criteria-guided selection of alternative zinc-binding groups of HDAC3 inhibitors using in silico and in vitro approaches"],"prefix":"10.1016","volume":"143","author":[{"given":"Thabo Brighton","family":"Makgoba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Egieyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Kapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0378-7091","authenticated-orcid":false,"given":"Jacques","family":"Joubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bmc.2026.118810_bb0005","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41419-021-04019-6","article-title":"The critical roles of histone deacetylase 3 in the pathogenesis of solid organ injury","volume":"12","author":"Ning","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.bmc.2026.118810_bb0010","doi-asserted-by":"crossref","unstructured":"Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000;403(6765):41\u201345 (2000). Doi: https:\/\/doi.org\/10.1038\/47412.","DOI":"10.1038\/47412"},{"issue":"5","key":"10.1016\/j.bmc.2026.118810_bb0015","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1177\/1073858418780971","article-title":"Aging in the brain: new roles of epigenetics in cognitive decline","volume":"24","author":"Barter","year":"2018","journal-title":"Neuroscientist"},{"issue":"8","key":"10.1016\/j.bmc.2026.118810_bb0020","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2174\/1570159X18666200128125641","article-title":"Alzheimer\u2019s disorder: epigenetic connection and associated risk factors","volume":"18","author":"Sharma","year":"2020","journal-title":"CN"},{"issue":"1","key":"10.1016\/j.bmc.2026.118810_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010369","article-title":"Synthesis, molecular docking and biological characterization of pyrazine linked 2-aminobenzamides as new class I selective histone deacetylase (HDAC) inhibitors with anti-leukemic activity","volume":"23","author":"Ibrahim","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.bmc.2026.118810_bb0030","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res"},{"key":"10.1016\/j.bmc.2026.118810_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114470","article-title":"Selective inhibition of histone deacetylase 3 by novel hydrazide based small molecules as therapeutic intervention for the treatment of cancer","volume":"238","author":"Pulya","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"4","key":"10.1016\/j.bmc.2026.118810_bb0040","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4155\/fmc.12.3","article-title":"Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed","volume":"4","author":"Gryder","year":"2012","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bmc.2026.118810_bb0045","doi-asserted-by":"crossref","DOI":"10.1177\/13872877241288709","article-title":"The impact of sex on memory during aging and Alzheimer\u2019s disease progression: epigenetic mechanisms","author":"Scheinman","year":"2024","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.bmc.2026.118810_bb0050","article-title":"Spirotetrahydroisoquinoline-based histone deacetylase inhibitors as new antifibrotic agents: biological evaluation in human fibroblasts from bronchoalveolar lavages of idiopathic pulmonary fibrosis patients","author":"Fontana","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"1","key":"10.1016\/j.bmc.2026.118810_bb0055","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0006-291X(69)90661-5","article-title":"Enzymatic deacetylation of histone","volume":"36","author":"Inoue","year":"1969","journal-title":"Biochem Biophys Res Commun"},{"issue":"5260","key":"10.1016\/j.bmc.2026.118810_bb0060","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.272.5260.408","article-title":"A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p","volume":"272","author":"Taunton","year":"1996","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bmc.2026.118810_bb0065","doi-asserted-by":"crossref","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"5","key":"10.1016\/j.bmc.2026.118810_bb0070","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1021\/acschemneuro.0c00721","article-title":"PT3: A novel benzamide class histone deacetylase 3 inhibitor improves learning and memory in novel object recognition mouse model","volume":"12","author":"Pulya","year":"2021","journal-title":"ACS Chem Neurosci"},{"issue":"10","key":"10.1016\/j.bmc.2026.118810_bb0075","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202301762RR","article-title":"Histone deacetylase-3 regulates the expression of the amyloid precursor protein and its inhibition promotes neuroregenerative pathways in Alzheimer\u2019s disease models","volume":"38","author":"Davis","year":"2024","journal-title":"FASEB J"},{"key":"10.1016\/j.bmc.2026.118810_bb0080","doi-asserted-by":"crossref","unstructured":"Meleady L, Towriss M, Kim J, Bacarac V, Dang V, Rowland ME, et al. Histone deacetylase 3 regulates microglial function through histone deacetylation. Epigenetics 2023;18(1):2241008. doi:https:\/\/doi.org\/10.1080\/15592294.2023.2241008 [PubMed PMID: 37506371; PubMed Central PMCID: PMC10392760].","DOI":"10.1080\/15592294.2023.2241008"},{"issue":"5","key":"10.1016\/j.bmc.2026.118810_bb0085","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s12975-020-00783-3","article-title":"Neuroprotective effects of selective inhibition of histone deacetylase 3 in experimental stroke","volume":"11","author":"Matheson","year":"2020","journal-title":"Transl Stroke Res"},{"issue":"1","key":"10.1016\/j.bmc.2026.118810_bb0090","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s12035-022-03083-z","article-title":"Histone deacetylase 3 inhibition decreases cerebral edema and protects the blood\u2013brain barrier after stroke","volume":"60","author":"Lu","year":"2023","journal-title":"Mol Neurobiol"},{"issue":"6","key":"10.1016\/j.bmc.2026.118810_bb0095","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm Sin B"},{"issue":"10","key":"10.1016\/j.bmc.2026.118810_bb0100","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"10.1016\/j.bmc.2026.118810_bb0105","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1007\/s10637-010-9447-x","article-title":"A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors","volume":"29","author":"Dickson","year":"2011","journal-title":"Investig New Drugs"},{"issue":"21","key":"10.1016\/j.bmc.2026.118810_bb0110","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1021\/jm900648x","article-title":"Hydroxamates: relationships between structure and plasma stability","volume":"52","author":"Flipo","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118810_bb0115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sbi.2019.01.004","article-title":"Structure, mechanism, and inhibition of the zinc-dependent histone deacetylases","volume":"59","author":"Porter","year":"2019","journal-title":"Curr Opin Struct Biol"},{"issue":"48","key":"10.1016\/j.bmc.2026.118810_bb0120","doi-asserted-by":"crossref","first-page":"20686","DOI":"10.1073\/pnas.1010950107","article-title":"Detoxifying carcinogenic polyhalogenated quinones by hydroxamic acids via an unusual double Lossen rearrangement mechanism","volume":"107","author":"Zhu","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"10.1016\/j.bmc.2026.118810_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26175151","article-title":"Non-hydroxamate zinc-binding groups as warheads for histone deacetylases","volume":"26","author":"Fr\u00fchauf","year":"2021","journal-title":"Molecules"},{"issue":"21","key":"10.1016\/j.bmc.2026.118810_bb0130","doi-asserted-by":"crossref","first-page":"9067","DOI":"10.1021\/acs.jmedchem.7b01444","article-title":"Controlling plasma stability of hydroxamic acids: A MedChem toolbox","volume":"60","author":"Hermant","year":"2017","journal-title":"J Med Chem"},{"issue":"17","key":"10.1016\/j.bmc.2026.118810_bb0135","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000029049","article-title":"Design, synthesis, and biological evaluation of histone deacetylase inhibitor with novel salicylamide zinc binding group","volume":"101","author":"Kim","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bmc.2026.118810_bb0140","doi-asserted-by":"crossref","unstructured":"Kraft FB, Biermann L, Sch\u00e4ker-H\u00fcbner L, Hanl M, Hamacher A, Kassack MU, et al. Hydrazide-based class I HDAC inhibitors with HDAC3 preference completely reverse chemoresistance in a synergistic manner in platinum-resistant solid cancer cells [Internet]. Chemistry; 2024 [cited 2025 Jan 8]. Available from: https:\/\/chemrxiv.org\/engage\/chemrxiv\/article-details\/66868aba01103d79c5fd2b7b doi:10.26434\/chemrxiv-2024-txxrk.","DOI":"10.26434\/chemrxiv-2024-txxrk-v2"},{"key":"10.1016\/j.bmc.2026.118810_bb0145","doi-asserted-by":"crossref","unstructured":"Bieszczad KM, Bechay K, Rusche JR, Jacques V, Kudugunti S, Miao W, et al. Histone deacetylase inhibition via RGFP966 releases the brakes on sensory cortical plasticity and the specificity of memory formation. J Neurosci 2015;35(38):13124\u201332. doi:https:\/\/doi.org\/10.1523\/JNEUROSCI.0914-15.2015 PubMed PMID: 26400942; PubMed Central PMCID: PMC4579377.","DOI":"10.1523\/JNEUROSCI.0914-15.2015"},{"key":"10.1016\/j.bmc.2026.118810_bb0150","doi-asserted-by":"crossref","unstructured":"Xu L, An T, Jia B, Wu Q, Shen J, Jin J, et al. Histone deacetylase 3-specific inhibitor RGFP966 attenuates oxidative stress and inflammation after traumatic brain injury by activating the Nrf2 pathway. Burns Trauma 2024;12:tkad062. doi:https:\/\/doi.org\/10.1093\/burnst\/tkad062 [PubMed PMID: 38708192; PubMed Central PMCID: PMC11069425].","DOI":"10.1093\/burnst\/tkad062"},{"key":"10.1016\/j.bmc.2026.118810_bb0155","unstructured":"Molecular Operating Environment (MOE) [Internet]. .0601 Chemical Computing Group ULC, 910-1010 Sherbrooke St. W., Montreal, QC H3A 2R7: Chemical Computing Group. Available from: https:\/\/www.chemcomp.com\/en\/index.htm."},{"key":"10.1016\/j.bmc.2026.118810_bb0160","unstructured":"SAVESv6.1 - Structure Validation Server [Internet]. [cited 2025 Mar 12]. Available from: https:\/\/saves.mbi.ucla.edu\/."},{"issue":"6364","key":"10.1016\/j.bmc.2026.118810_bb0165","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/356083a0","article-title":"Assessment of protein models with three-dimensional profiles","volume":"356","author":"L\u00fcthy","year":"1992","journal-title":"Nature"},{"issue":"5016","key":"10.1016\/j.bmc.2026.118810_bb0170","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1126\/science.1853201","article-title":"A method to identify protein sequences that fold into a known three-dimensional structure","volume":"253","author":"Bowie","year":"1991","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bmc.2026.118810_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18010137","article-title":"A thoroughly validated virtual screening strategy for discovery of novel HDAC3 inhibitors","volume":"18","author":"Hu","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.bmc.2026.118810_bb0180","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41598-022-05698-7","article-title":"Identification of novel leads as potent inhibitors of HDAC3 using ligand-based pharmacophore modeling and MD simulation","volume":"12","author":"Kumbhar","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2026.118810_bb0185","first-page":"1","article-title":"Hydroxamic acid derivatives as selective HDAC3 inhibitors: computer-aided drug design strategies","author":"Patel","year":"2023","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.bmc.2026.118810_bb0190","unstructured":"Zentrum f\u00fcr Bioinformatik: Universit\u00e4t Hamburg - Proteins Plus Server [Internet]. [cited 2025 Mar 12]. Available from: https:\/\/proteins.plus\/."},{"issue":"5","key":"10.1016\/j.bmc.2026.118810_bb0195","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1021\/ci500062f","article-title":"An unbiased method to build benchmarking sets for ligand-based virtual screening and its application to GPCRs","volume":"54","author":"Xia","year":"2014","journal-title":"J Chem Inf Model"},{"issue":"2","key":"10.1016\/j.bmc.2026.118810_bb0200","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1021\/ci5005515","article-title":"Comparative modeling and benchmarking data sets for human histone deacetylases and sirtuin families","volume":"55","author":"Xia","year":"2015","journal-title":"J Chem Inf Model"},{"issue":"16","key":"10.1016\/j.bmc.2026.118810_bb0205","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01943-16","article-title":"Epigenetic metabolite acetate inhibits class I\/II histone deacetylases, promotes histone acetylation, and increases HIV-1 integration in CD4+ T cells","volume":"91","author":"Bolduc","year":"2017","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.bmc.2026.118810_bb0210","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00125-020-05305-2","article-title":"\u03b2-Hydroxybutyrate inhibits histone deacetylase 3 to promote claudin-5 generation and attenuate cardiac microvascular hyperpermeability in diabetes","volume":"64","author":"Li","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.bmc.2026.118810_bb0215","doi-asserted-by":"crossref","unstructured":"Sealy L, Chalkley R. The effect of sodium butyrate on histone modification. Cell 1978;14(1):115\u201321. doi:https:\/\/doi.org\/10.1016\/0092-8674(78)90306-9 [PubMed PMID: 667928].","DOI":"10.1016\/0092-8674(78)90306-9"},{"issue":"24","key":"10.1016\/j.bmc.2026.118810_bb0220","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"G\u00f6ttlicher","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.bmc.2026.118810_bb0225","doi-asserted-by":"crossref","unstructured":"Elengoe A, Naser MA, Hamdan S. Modeling and docking studies on novel mutants (K71L and T204V) of the ATPase domain of human heat shock 70 kDa protein 1. Int J Mol Sci 2014;15(4):4. doi:https:\/\/doi.org\/10.3390\/ijms15046797.","DOI":"10.3390\/ijms15046797"},{"issue":"7","key":"10.1016\/j.bmc.2026.118810_bb0230","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1007\/s00894-014-2340-3","article-title":"Homology modeling and protein engineering of alkane monooxygenase in Burkholderia thailandensis MSMB121: in silico insights","volume":"20","author":"Jain","year":"2014","journal-title":"J Mol Model"},{"issue":"sup2","key":"10.1016\/j.bmc.2026.118810_bb0235","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/14756366.2016.1193736","article-title":"Reliability analysis and optimization of the consensus docking approach for the development of virtual screening studies","volume":"31","author":"Poli","year":"2016","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"15","key":"10.1016\/j.bmc.2026.118810_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155183","article-title":"Assessing molecular docking tools to guide targeted drug discovery of CD38 inhibitors","volume":"21","author":"Boittier","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2026.118810_bb0245","doi-asserted-by":"crossref","unstructured":"C S, S. DK, Ragunathan V, Tiwari P, A. S, P BD. Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of natural compounds against the SARS-CoV-2 main-protease. J Biomol Struct Dyn 2022;40(2):585\u2013611. doi:https:\/\/doi.org\/10.1080\/07391102.2020.1815584.","DOI":"10.1080\/07391102.2020.1815584"},{"issue":"3","key":"10.1016\/j.bmc.2026.118810_bb0250","doi-asserted-by":"crossref","DOI":"10.1002\/minf.202000105","article-title":"HDAC3i-finder: a machine learning-based computational tool to screen for HDAC3 inhibitors","volume":"40","author":"Li","year":"2021","journal-title":"Mol Inform"},{"key":"10.1016\/j.bmc.2026.118810_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00260","article-title":"Improving docking performance using negative image-based rescoring","volume":"9","author":"Kurkinen","year":"2018","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.bmc.2026.118810_bb0260","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/1568026619666190122144949","article-title":"Zinc-dependent deacetylase (HDAC) inhibitors with different zinc binding groups","volume":"19","author":"Li","year":"2019","journal-title":"Curr Top Med Chem"},{"issue":"7381","key":"10.1016\/j.bmc.2026.118810_bb0265","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature10728","article-title":"Structure of HDAC3 bound to co-repressor and inositol tetraphosphate","volume":"481","author":"Watson","year":"2012","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bmc.2026.118810_bb0270","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/molecules27082526","article-title":"Docking, binding free energy calculations and in vitro characterization of pyrazine linked 2-aminobenzamides as novel class I histone deacetylase (HDAC) inhibitors","volume":"27","author":"B\u00fclb\u00fcl","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2026.118810_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112171","article-title":"Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review","volume":"192","author":"Sarkar","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"4","key":"10.1016\/j.bmc.2026.118810_bb0280","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/13543776.2024.2363890","article-title":"HDAC3 inhibitors: a patent review of their broad-spectrum applications as therapeutic agents","volume":"34","author":"Makgoba","year":"2024","journal-title":"Expert Opin Ther Pat"},{"issue":"9","key":"10.1016\/j.bmc.2026.118810_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127075","article-title":"Discovery of 9-phenylacridinediones as highly selective butyrylcholinesterase inhibitors through structure-based virtual screening","volume":"30","author":"Joubert","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"issue":"9","key":"10.1016\/j.bmc.2026.118810_bb0290","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1021\/jm049032d","article-title":"HierS: hierarchical scaffold clustering using topological chemical graphs","volume":"48","author":"Wilkens","year":"2005","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.bmc.2026.118810_bb0295","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1021\/acsmedchemlett.0c00462","article-title":"Discovery of highly selective and potent HDAC3 inhibitors based on a 2-substituted benzamide zinc binding group","volume":"11","author":"Liu","year":"2020","journal-title":"ACS Med Chem Lett"},{"issue":"6","key":"10.1016\/j.bmc.2026.118810_bb0300","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.sbi.2011.08.004","article-title":"Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes","volume":"21","author":"Lombardi","year":"2011","journal-title":"Curr Opin Struct Biol"},{"issue":"18","key":"10.1016\/j.bmc.2026.118810_bb0305","first-page":"1","article-title":"Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis","volume":"10","author":"Li","year":"2011","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.bmc.2026.118810_bb0310","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/14756366.2018.1437156","article-title":"The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay","volume":"33","author":"Xia","year":"2018","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmc.2026.118810_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105050","article-title":"Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors","volume":"114","author":"Routholla","year":"2021","journal-title":"Bioorg Chem"},{"issue":"6","key":"10.1016\/j.bmc.2026.118810_bb0320","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.therap.2018.02.004","article-title":"Safety data and withdrawal of hepatotoxic drugs","volume":"76","author":"Babai","year":"2021","journal-title":"Therapies"},{"key":"10.1016\/j.bmc.2026.118810_bb0325","article-title":"Histone deacetylases and their inhibitors in inflammatory diseases","volume":"179","author":"Zhang","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"10.1016\/j.bmc.2026.118810_bb0330","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.bcp.2004.05.022","article-title":"Effect of the histone deacetylase inhibitor trichostatin A on spontaneous apoptosis in various types of adult rat hepatocyte cultures","volume":"68","author":"Vanhaecke","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmc.2026.118810_bb0335","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1333235","article-title":"Trichostatin A relieves anxiety-and depression-like symptoms in APP\/PS1 mice","volume":"15","author":"Su","year":"2024","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.bmc.2026.118810_bb0340","first-page":"2110","article-title":"Definition of a continuous human cell line derived from neuroblastoma","volume":"30","author":"Tumilowicz","year":"1970","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2026.118810_bb0345","unstructured":"Heghes A, Semenescu AD, Moise G, Predescu IA, Trandafirescu C, Antal DS, et al. Genistein: a preliminary in vitro evaluation on IMR-32 neuroblastoma cells. Curr Health Sci J 2025;51(2):191\u20137. doi:10.12865\/CHSJ.51.02.03 [PubMed PMID: 41262999; PubMed Central PMCID: PMC12625783]."},{"issue":"17","key":"10.1016\/j.bmc.2026.118810_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26175319","article-title":"Imidazopyridazine acetylcholinesterase inhibitors display potent anti-proliferative effects in the human neuroblastoma cell-line, IMR-32","volume":"26","author":"Sharma","year":"2021","journal-title":"Molecules"},{"issue":"23","key":"10.1016\/j.bmc.2026.118810_bb0355","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313135","article-title":"The curious case of the HepG2 cell line: 40 years of expertise","volume":"22","author":"Arzumanian","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"20","key":"10.1016\/j.bmc.2026.118810_bb0360","doi-asserted-by":"crossref","first-page":"14121","DOI":"10.1021\/acs.jmedchem.2c01336","article-title":"Discovery and characterization of potent, efficacious, orally available antimalarial Plasmepsin X inhibitors and preclinical safety assessment of UCB7362","volume":"65","author":"Lowe","year":"2022","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bmc.2026.118810_bb0365","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3390\/toxics12020126","article-title":"In vitro toxicity screening of fifty complex mixtures in HepG2 cells","volume":"12","author":"Kim","year":"2024","journal-title":"Toxics"},{"key":"10.1016\/j.bmc.2026.118810_bb0370","unstructured":"https:\/\/www.atcc.org [Internet]. [cited 2026 Jul 14]. Hep G2 [HEPG2] - HB-8065 | ATCC. Available from: https:\/\/www.atcc.org\/products\/hb-8065."},{"issue":"3","key":"10.1016\/j.bmc.2026.118810_bb0375","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11481-006-9025-3","article-title":"Blood\u2013brain barrier: structural components and function under physiologic and pathologic conditions","volume":"1","author":"Persidsky","year":"2006","journal-title":"J Neuroimmune Pharm"},{"issue":"11","key":"10.1016\/j.bmc.2026.118810_bb0380","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood\u2013brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J Cereb Blood Flow Metab"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962600266X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962600266X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:37:14Z","timestamp":1792067834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096808962600266X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":76,"alternative-id":["S096808962600266X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118810","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Criteria-guided selection of alternative zinc-binding groups of HDAC3 inhibitors using in silico and in vitro approaches","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118810","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"118810"}}